Alvotech (ALVO) Q3 2024 earnings summary

Executive summary

• Total revenues for the first nine months of 2024 increased nearly ninefold year-over-year, reaching $339 million, driven by product launches and milestone revenues.

• Adjusted EBITDA turned positive for the second consecutive quarter, totaling $87 million for the first nine months, a significant turnaround from the prior year.

• Major product launches and regulatory milestones included biosimilars to Humira, Stelara, and upcoming candidates for Eylea, Simponi, Prolia, and Xgeva, with global launches in the US, Canada, Japan, and Europe.

• FDA completed a GMP inspection of the Iceland manufacturing site, resulting in two minor observations with no impact on product launches.

• Expanded global footprint and strong partner sales, with further market expansion expected.

Financial highlights

• Product revenues for the first nine months rose to $128 million, up over four-fold year-over-year, with Q3 product revenues at $62 million.

• Milestone and license revenues surged to $211 million, reflecting pipeline progression and new deals.

• Q3 product margin improved to 37% from 17% in Q2, driven by higher U.S. shipments and European launches.

• Operating profit for the first nine months was $56 million, a $344 million improvement from the prior year; adjusted EBITDA reached $87 million versus negative $225 million year-over-year.

• Cash on hand at quarter-end was $118 million, with borrowings of approximately $1.03 billion.

Outlook and guidance

• Revenue guidance for 2024 remains $400 million–$500 million, with milestone revenues expected to be slightly higher than initially guided.

• Fourth quarter expected to be the strongest for product shipments, though some may spill into Q1 2025.

• 2025 preliminary revenue guidance of $600 million–$800 million remains in place pending finalization of commercial negotiations.

• SELARSDI US launch expected in February 2025, with final approval upon exclusivity expiry in April 2025.

• Sufficient cash runway to reach free cash flow positive based on current operating plans.